NPI: 1518021310 · CLIFTON SPRINGS, NY 14432 · Psychiatric Hospital Unit · NPI assigned 12/19/2006
Authorized official TINCH, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | TINCH, PAULA (SVP, FINANCE) |
| NPI Enumeration Date | 12/19/2006 |
Other providers sharing the same authorized official: TINCH, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 45 | $4K |
| 2019 | 694 | $42K |
| 2020 | 2,889 | $158K |
| 2021 | 4,219 | $346K |
| 2022 | 5,969 | $450K |
| 2023 | 5,561 | $436K |
| 2024 | 3,344 | $367K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90791 | Psychiatric diagnostic evaluation | 1,382 | 1,165 | $758K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1,918 | 1,755 | $237K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1,698 | 1,584 | $201K |
| 90832 | Psychotherapy, 30 minutes with patient | 1,772 | 1,249 | $169K |
| 90834 | Psychotherapy, 45 minutes with patient | 1,162 | 733 | $153K |
| 36415 | Collection of venous blood by venipuncture | 2,081 | 1,820 | $44K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 302 | 271 | $41K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 487 | 438 | $35K |
| 80053 | Comprehensive metabolic panel | 2,318 | 2,170 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,150 | 1,006 | $18K |
| S9485 | Crisis intervention mental health services, per diem | 15 | 14 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 291 | 281 | $16K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 110 | 107 | $13K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 85 | 78 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | 1,471 | 1,437 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 234 | 233 | $6K |
| H2011 | Crisis intervention service, per 15 minutes | 90 | 68 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | 618 | 613 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 234 | 234 | $5K |
| 80061 | Lipid panel | 740 | 736 | $4K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 78 | 25 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 30 | 27 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2,359 | 2,170 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | 209 | 187 | $3K |
| 99222 | Initial hospital care, per day, moderate complexity | 17 | 17 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13 | 12 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 64 | 64 | $2K |
| 87660 | 99 | 99 | $799.35 | |
| 85027 | 263 | 255 | $788.82 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12 | 12 | $613.51 |
| 87631 | 14 | 14 | $599.61 | |
| 82607 | 56 | 55 | $572.18 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 127 | 121 | $411.57 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 480 | 423 | $329.92 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 32 | 32 | $281.70 |
| 84702 | 111 | 103 | $210.77 | |
| 84439 | 28 | 27 | $207.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 12 | 12 | $168.03 |
| 81001 | 148 | 147 | $149.67 | |
| 83735 | 41 | 40 | $89.27 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 13 | 13 | $66.50 |
| 81025 | 28 | 26 | $66.10 | |
| 71046 | Radiologic examination, chest; 2 views | 13 | 13 | $33.33 |
| 83690 | 53 | 50 | $5.81 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 111 | 108 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 54 | 53 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 31 | 25 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 67 | 63 | $0.00 |